From perforated seals and breakable caps to shrink bands and peel-back blister packs, these features act as the first line of defence against tampering, contamination, and counterfeiting. In a sector where product integrity can be a matter of life and death, tamper-evident packaging provides reassurance to healthcare professionals, pharmacists, and patients that medications are safe and authentic.
In this blog, we will explore why tamper-evident packaging is essential to the pharmaceutical industry, how it helps prevent unauthorised access and counterfeiting, and how integrating tamper evidence with serialisation and track-and-trace systems can further enhance supply chain security.
Regulatory importance of tamper-evident pharmaceutical packaging
In the UK and across Europe, tamper-evident pharmaceutical packaging is a mandatory requirement for most prescription medicines. It is a critical measure to safeguard patients and prevent falsified products from entering the legal supply chain. Regulatory bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) enforce strict packaging standards to ensure every pharmaceutical product can be verified as genuine and untampered.
Under the EU Falsified Medicines Directive (2011/62/EU), implemented in the UK through the Human Medicines Regulations, all prescription medicines must carry a unique identifier and an anti-tampering device. These features make interference immediately visible, allowing pharmacists and patients to verify that products are genuine and unopened.
Although the UK now operates independently from the EU, the MHRA continues to align closely with these standards, ensuring packaging remains both compliant and secure. For pharmaceutical manufacturers, using tamper-evident features is not just about meeting regulations, it’s about demonstrating a clear commitment to patient safety and product integrity.